☰

Chioniso P. Masamha, Ph.D. - Publications

Affiliations: 
2010 University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States 
Area:
Biochemistry, Cell Biology, Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

17 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Marjamaa A, Gibbs B, Kotrba C, Masamha CP. The role and impact of alternative polyadenylation and miRNA regulation on the expression of the multidrug resistance-associated protein 1 (MRP-1/ABCC1) in epithelial ovarian cancer. Scientific Reports. 13: 17476. PMID 37838788 DOI: 10.1038/s41598-023-44548-y  0.367
2019 Weng T, Ko J, Masamha CP, Xia Z, Xiang Y, Chen NY, Molina JG, Collum S, Mertens TC, Luo F, Philip K, Davies J, Huang J, Wilson C, Thandavarayan RA, et al. Cleavage factor 25 deregulation contributes to pulmonary fibrosis through alternative polyadenylation. The Journal of Clinical Investigation. 130. PMID 30830875 DOI: 10.1172/Jci122106  0.319
2018 Park HJ, Ji P, Kim S, Xia Z, Rodriguez B, Li L, Su J, Chen K, Masamha CP, Baillat D, Fontes-Garfias CR, Shyu AB, Neilson JR, Wagner EJ, Li W. 3' UTR shortening represses tumor-suppressor genes in trans by disrupting ceRNA crosstalk. Nature Genetics. PMID 29785014 DOI: 10.1038/S41588-018-0118-8  0.322
2018 Masamha CP, Todd Z. Adapting 3' Rapid Amplification of CDNA Ends to Map Transcripts in Cancer. Journal of Visualized Experiments : Jove. PMID 29658915 DOI: 10.3791/57318  0.313
2018 Masamha CP, LaFontaine P. Molecular targeting of glutaminase sensitizes ovarian cancer cells to chemotherapy. Journal of Cellular Biochemistry. PMID 29633308 DOI: 10.1002/Jcb.26814  0.558
2017 Benbrook DM, Janakiram NB, Chandra V, Pathuri G, Madka V, Stratton NC, Masamha CP, Farnsworth CN, Garcia-Contreras L, Hatipoglu MK, Lighfoot S, Rao CV. Development of a dietary formulation of the SHetA2 chemoprevention drug for mice. Investigational New Drugs. PMID 29273857 DOI: 10.1007/S10637-017-0550-0  0.558
2017 Masamha CP, Wagner EJ. The contribution of alternative polyadenylation to the cancer phenotype. Carcinogenesis. PMID 28968750 DOI: 10.1093/Carcin/Bgx096  0.397
2017 Masamha CP. The drive to generate multiple forms of oncogenic cyclin D1 transcripts in mantle cell lymphoma. Biomarker Research. 5: 16. PMID 28503306 DOI: 10.1186/S40364-017-0094-7  0.408
2017 Masamha CP, LaFontaine P, Gibbs BE. Abstract 5418: Deciphering the dynamics of alternative pre-mRNA processing of glutaminase in metastatic ovarian cancer Cancer Research. 77: 5418-5418. DOI: 10.1158/1538-7445.Am2017-5418  0.407
2017 Chandra V, Long A, Masamha CP, Benbrook DM. Abstract 3308: Mitophagy induction and interference with cancer-specific apoptosis in SHetA2-treated cells Cancer Research. 77: 3308-3308. DOI: 10.1158/1538-7445.Am2017-3308  0.663
2016 Masamha CP, Xia Z, Peart N, Collum S, Li W, Wagner EJ, Shyu AB. CFIm25 regulates glutaminase alternative terminal exon definition to modulate miR-23 function. Rna (New York, N.Y.). PMID 27095025 DOI: 10.1261/Rna.055939.116  0.358
2016 Masamha CP, Albrecht TR, Wagner EJ. Discovery and characterization of a novel CCND1/MRCK gene fusion in mantle cell lymphoma. Journal of Hematology & Oncology. 9: 30. PMID 27025456 DOI: 10.1186/S13045-016-0260-7  0.422
2014 Masamha CP, Xia Z, Yang J, Albrecht TR, Li M, Shyu AB, Li W, Wagner EJ. CFIm25 links alternative polyadenylation to glioblastoma tumour suppression. Nature. 510: 412-6. PMID 24814343 DOI: 10.1038/Nature13261  0.433
2011 Benbrook DM, Masamha CP. The pro-survival function of Akt kinase can be overridden or altered to contribute to induction of apoptosis. Current Cancer Drug Targets. 11: 586-99. PMID 21486222 DOI: 10.2174/156800911795655994  0.597
2009 Masamha CP, Benbrook DM. Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells. Cancer Research. 69: 6565-72. PMID 19638577 DOI: 10.1158/0008-5472.Can-09-0913  0.655
2009 Liu T, Masamha CP, Chengedza S, Berlin KD, Lightfoot S, He F, Benbrook DM. Development of flexible-heteroarotinoids for kidney cancer. Molecular Cancer Therapeutics. 8: 1227-38. PMID 19417155 DOI: 10.1158/1535-7163.Mct-08-1069  0.522
2008 Masamha C, Benbrook D. Abstract A13: Chemoprevention agent SHetA2 induces G1 arrest through modulation of a biological system driven by Cyclin D1 Cancer Prevention Research. 1. DOI: 10.1158/1940-6207.Prev-08-A13  0.653
Show low-probability matches.